NovaMab completes first GMP ADC campaign in its contained facility
A site-specific conjugation programme reached GMP drug-substance supply, demonstrating contained handling of a cytotoxic payload at OEB-controlled scale.
Read more →Specialized biologic modalities
Specialized modalities, made manufacturable.
NovaMab takes next-generation antibodies and conjugates from concept to GMP — with the contained, high-potency facilities and the specialised analytics that complex modalities demand. Antibody-drug conjugates, engineered formats and adjacent modalities, built to scale with a confident regulatory story.
The challenge
Scaling emerging science into compliant manufacturing
Complex modalities rarely fail on the biology — they stall on the path to the clinic. Conjugates and engineered formats demand contained handling of cytotoxic payloads, analytics that can resolve drug-to-antibody ratio and free drug, and a CMC narrative regulators trust. We exist to turn promising specialized science into a process that can be made, characterised and supplied to GMP.
Modalities we build
The right platform for each modality
01
Develop
Feasibility & design
Confirm the modality can be made and characterised.
02
Engineer
Chemistry & format
Conjugation route and engineered format, in step.
03
Scale
Process & analytics
Scalable process with a defined analytical package.
04
GMP
Contained supply
Contained GMP drug substance and clinical supply.
Antibody-drug conjugates
Site-specific and stochastic conjugation, linker-payload selection and DAR control to deliver homogeneous, well-characterised conjugates for cytotoxic and high-potency programmes.
Engineered antibody formats
Bispecifics, fragments and Fc-engineering — format engineering and process development for next-generation, non-standard formats built for manufacturability.
Why NovaMab
Purpose-built for complex modalities, not generic biologics.
Modality specialists
Conjugation chemistry, engineered antibody formats and adjacent modalities are our core — not a sideline. The scientists who scope your programme have built these molecules before.
Contained high-potency capability
Cytotoxic payloads and potent intermediates are handled to high containment (OEB) standards, protecting operators and product while keeping conjugation chemistry under control.
Regulatory confidence
Every process is built with a credible CMC and regulatory story — analytics, comparability and control strategy designed so emerging science survives the journey to GMP.
Latest news
What's new at NovaMab
Case study: site-specific conjugation delivers a homogeneous DAR-2 ADC
Enzymatic conjugation produced a narrowly distributed drug-to-antibody ratio, improving the analytical and stability profile of a partner's conjugate.
Read more →NovaMab expands mRNA/LNP development capability
New mRNA drug-substance and lipid-nanoparticle formulation capability broadens our support for emerging modalities alongside antibodies and conjugates.
Read more →Have a complex modality to take to GMP?
Tell us about your conjugate, engineered format or emerging modality and the manufacturing hurdle you're facing. We'll tell you candidly how we'd make it manufacturable.